Halozyme Therapeutics Inc (HALO)

[jamtomorrow2]

Well we all knew that the data would be muddled. The Phase 1 & 2 trials with the halt and introduction of the Ventana diagnostic were bound to lead to muddled data. But I do think that HALO's presentation of all the data was thorough and fair albeit confusing for those who can't be bothered to understand all the implications of the trial problems. So now the big bad news data that AF and AB are focusing on is the overall OS data being worse than control, which HALO claims is skewed by one control patient living much longer than expected. I guess the claim about how one patient in a very small trial can skew the data of course could also work the other way round. I would therefore imagine that there is no chance of HALO submitting an NDA based on this data and therefore we are in for a long wait - hence the market disappoint.